{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T15:30:41Z","timestamp":1758123041447,"version":"3.37.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2016,10,17]],"date-time":"2016-10-17T00:00:00Z","timestamp":1476662400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","award":["-"],"award-info":[{"award-number":["-"]}],"id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1007\/s00417-016-3511-y","type":"journal-article","created":{"date-parts":[[2016,10,17]],"date-time":"2016-10-17T17:27:03Z","timestamp":1476725223000},"page":"2401-2409","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Effects of intravitreally injected Fc fragment on rat eyes"],"prefix":"10.1007","volume":"254","author":[{"given":"Tatjana","family":"Taubitz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura-Pia","family":"Steinbrenner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander V.","family":"Tschulakow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antje","family":"Biesemeier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvie","family":"Julien-Schraermeyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Schraermeyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,10,17]]},"reference":[{"key":"3511_CR1","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/j.1600-065X.2006.00430.x","volume":"213","author":"TA Ferguson","year":"2006","unstructured":"Ferguson TA, Griffith TS (2006) A vision of cell death: Fas ligand and immune privilege 10 years later. Immunol Rev 213:228\u2013238. doi: 10.1111\/j.1600-065X.2006.00430.x","journal-title":"Immunol Rev"},{"key":"3511_CR2","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1038\/eye.2008.382","volume":"23","author":"AW Taylor","year":"2009","unstructured":"Taylor AW (2009) Ocular immune privilege. Eye (Lond) 23:1885\u20131889. doi: 10.1038\/eye.2008.382","journal-title":"Eye (Lond)"},{"key":"3511_CR3","doi-asserted-by":"publisher","first-page":"943409","DOI":"10.1155\/2013\/943409","volume":"2013","author":"S Agrawal","year":"2013","unstructured":"Agrawal S, Joshi M, Christoforidis JB (2013) Vitreous inflammation associated with intravitreal anti-VEGF pharmacotherapy. Mediators Inflamm 2013:943409. doi: 10.1155\/2013\/943409","journal-title":"Mediators Inflamm"},{"key":"3511_CR4","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ophtha.2015.06.040","volume":"123","author":"P Hahn","year":"2016","unstructured":"Hahn P, Yashkin AP, Sloan FA (2016) Effect of prior anti-VEGF injections on the risk of retained lens fragments and endophthalmitis after cataract surgery in the elderly. Ophthalmology 123:309\u2013315. doi: 10.1016\/j.ophtha.2015.06.040","journal-title":"Ophthalmology"},{"key":"3511_CR5","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/0014-4835(91)90225-4","volume":"53","author":"RC Tripathi","year":"1991","unstructured":"Tripathi RC, Borisuth NS, Tripathi BJ (1991) Mapping of Fc gamma receptors in the human and porcine eye. Exp Eye Res 53:647\u2013656","journal-title":"Exp Eye Res"},{"key":"3511_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2012-302308","author":"S Julien","year":"2012","unstructured":"Julien S, Biesemeier A, Schraermeyer U (2012) In vitro induction of protein complexes between bevacizumab, VEGF-A165 and heparin: explanation for deposits observed on endothelial veins in monkey eyes. Br J Ophthalmol. doi: 10.1136\/bjophthalmol-2012-302308","journal-title":"Br J Ophthalmol"},{"key":"3511_CR7","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1136\/bjophthalmol-2013-304019","volume":"98","author":"S Julien","year":"2014","unstructured":"Julien S, Biesemeier A, Taubitz T, Schraermeyer U (2014) Different effects of intravitreally injected ranibizumab and aflibercept on retinal and choroidal tissues of monkey eyes. Br J Ophthalmol 98:813\u2013825. doi: 10.1136\/bjophthalmol-2013-304019","journal-title":"Br J Ophthalmol"},{"key":"3511_CR8","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1517\/14712598.2012.748741","volume":"13","author":"U Schraermeyer","year":"2013","unstructured":"Schraermeyer U, Julien S (2013) Effects of bevacizumab in retina and choroid after intravitreal injection into monkey eyes. Expert Opin Biol Ther 13:157\u2013167. doi: 10.1517\/14712598.2012.748741","journal-title":"Expert Opin Biol Ther"},{"key":"3511_CR9","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1007\/s00417-012-2055-z","volume":"250","author":"U Schraermeyer","year":"2012","unstructured":"Schraermeyer U, Julien S (2012) Formation of immune complexes and thrombotic microangiopathy after intravitreal injection of bevacizumab in the primate eye. Graefes Arch Clin Exp Ophthalmol 250:1303\u20131313. doi: 10.1007\/s00417-012-2055-z","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"3511_CR10","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1055\/s-0034-1383142","volume":"232","author":"GE Lang","year":"2015","unstructured":"Lang GE, Lang GK, Deissler HL (2015) Basic in vitro studies on VEGF inhibition with aflibercept: similarities and differences to other VEGF-binding therapeutic proteins. Klin Monbl Augenheilkd 232:295\u2013302. doi: 10.1055\/s-0034-1383142","journal-title":"Klin Monbl Augenheilkd"},{"key":"3511_CR11","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.exer.2015.10.007","volume":"143","author":"HL Deissler","year":"2016","unstructured":"Deissler HL, Lang GK, Lang GE (2016) Internalization of bevacizumab by retinal endothelial cells and its intracellular fate: evidence for an involvement of the neonatal Fc receptor. Exp Eye Res 143:49\u201359. doi: 10.1016\/j.exer.2015.10.007","journal-title":"Exp Eye Res"},{"key":"3511_CR12","first-page":"4593","volume":"57","author":"LG Presta","year":"1997","unstructured":"Presta LG, Chen H, O\u2019Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, Ferrara N (1997) Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57:4593\u20134599","journal-title":"Cancer Res"},{"key":"3511_CR13","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s10456-011-9249-6","volume":"15","author":"N Papadopoulos","year":"2012","unstructured":"Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, Shi E, Pyles EA, Yancopoulos GD, Stahl N, Wiegand SJ (2012) Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 15:171\u2013185. doi: 10.1007\/s10456-011-9249-6","journal-title":"Angiogenesis"},{"key":"3511_CR14","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1177\/2040622312446007","volume":"3","author":"M Ohr","year":"2012","unstructured":"Ohr M, Kaiser PK (2012) Aflibercept in wet age-related macular degeneration: a perspective review. Ther Adv Chronic Dis 3:153\u2013161. doi: 10.1177\/2040622312446007","journal-title":"Ther Adv Chronic Dis"},{"key":"3511_CR15","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1097\/01.iae.0000242842.14624.e7","volume":"26","author":"N Ferrara","year":"2006","unstructured":"Ferrara N, Damico L, Shams N, Lowman H, Kim R (2006) Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 26:859\u2013870. doi: 10.1097\/01.iae.0000242842.14624.e7","journal-title":"Retina"},{"key":"3511_CR16","doi-asserted-by":"publisher","first-page":"8075","DOI":"10.1167\/iovs.15-17814","volume":"56","author":"Y Nomura","year":"2015","unstructured":"Nomura Y, Kaneko M, Miyata K, Yatomi Y, Yanagi Y (2015) Bevacizumab and Aflibercept activate platelets via Fc\u03b3RIIa. Invest Ophthalmol Vis Sci 56:8075\u20138082. doi: 10.1167\/iovs.15-17814","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3511_CR17","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/j.1538-7836.2008.03212.x","volume":"7","author":"T Meyer","year":"2009","unstructured":"Meyer T, Robles-Carrillo L, Robson T, Langer F, Desai H, Davila M, Amaya M, Francis JL, Amirkhosravi A (2009) Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice. J Thromb Haemost 7:171\u2013181. doi: 10.1111\/j.1538-7836.2008.03212.x","journal-title":"J Thromb Haemost"},{"key":"3511_CR18","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1007\/s00417-009-1136-0","volume":"247","author":"AK Klettner","year":"2009","unstructured":"Klettner AK, Kruse ML, Meyer T, Wesch D, Kabelitz D, Roider J (2009) Different properties of VEGF-antagonists: Bevacizumab but not Ranibizumab accumulates in RPE cells. Graefes Arch Clin Exp Ophthalmol 247:1601\u20131608. doi: 10.1007\/s00417-009-1136-0","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"3511_CR19","first-page":"2803","volume":"15","author":"H Kim","year":"2009","unstructured":"Kim H, Robinson SB, Csaky KG (2009) FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye. Mol Vis 15:2803\u20132812","journal-title":"Mol Vis"},{"key":"3511_CR20","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.exer.2015.12.013","volume":"145","author":"M Dithmer","year":"2016","unstructured":"Dithmer M, Hattermann K, Pomarius P, Aboul Naga SH, Meyer T, Mentlein R, Roider J, Klettner A (2016) The role of Fc-receptors in the uptake and transport of therapeutic antibodies in the retinal pigment epithelium. Exp Eye Res 145:187\u2013205. doi: 10.1016\/j.exer.2015.12.013","journal-title":"Exp Eye Res"},{"key":"3511_CR21","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.survophthal.2010.08.006","volume":"56","author":"M Tolentino","year":"2011","unstructured":"Tolentino M (2011) Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv Ophthalmol 56:95\u2013113. doi: 10.1016\/j.survophthal.2010.08.006","journal-title":"Surv Ophthalmol"},{"key":"3511_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0042701","volume":"7","author":"C Schmucker","year":"2012","unstructured":"Schmucker C, Ehlken C, Agostini HT, Antes G, Ruecker G, Lelgemann M, Loke YK (2012) A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard. PLoS One 7, e42701. doi: 10.1371\/journal.pone.0042701","journal-title":"PLoS One"},{"key":"3511_CR23","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1097\/IAE.0b013e3182278ab4","volume":"31","author":"MI Reis van der","year":"2011","unstructured":"van der Reis MI, La Heij EC, De Jong-Hesse Y, Ringens PJ, Hendrikse F, Schouten JS (2011) A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections. Retina 31:1449\u20131469. doi: 10.1097\/IAE.0b013e3182278ab4","journal-title":"Retina"},{"key":"3511_CR24","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s40264-015-0273-0","volume":"38","author":"YS Modi","year":"2015","unstructured":"Modi YS, Tanchon C, Ehlers JP (2015) Comparative safety and tolerability of anti-VEGF therapy in age-related macular degeneration. Drug Saf 38:279\u2013293. doi: 10.1007\/s40264-015-0273-0","journal-title":"Drug Saf"},{"key":"3511_CR25","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s00417-014-2733-0","volume":"253","author":"U Schraermeyer","year":"2015","unstructured":"Schraermeyer U, Julien S, Biesemeier A, Bartz-Schmidt KU, Wolburg H (2015) A new kind of labyrinth-like capillary is responsible for leakage from human choroidal neovascular endothelium, as investigated by high-resolution electron microscopy. Graefes Arch Clin Exp Ophthalmol 253:681\u2013689. doi: 10.1007\/s00417-014-2733-0","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"3511_CR26","doi-asserted-by":"publisher","first-page":"R1217","DOI":"10.1152\/ajpregu.00686.2011","volume":"303","author":"KK Sorensen","year":"2012","unstructured":"Sorensen KK, McCourt P, Berg T, Crossley C, Le Couteur D, Wake K, Smedsrod B (2012) The scavenger endothelial cell: a new player in homeostasis and immunity. Am J Physiol Regul Integr Comp Physiol 303:R1217\u2013R1230. doi: 10.1152\/ajpregu.00686.2011","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"3511_CR27","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1007\/s00018-010-0572-7","volume":"68","author":"N Niu","year":"2011","unstructured":"Niu N, Zhang J, Sun Y, Wang S, Sun Y, Korteweg C, Gao W, Gu J (2011) Expression and distribution of immunoglobulin G and its receptors in an immune privileged site: the eye. Cell Mol Life Sci 68:2481\u20132492. doi: 10.1007\/s00018-010-0572-7","journal-title":"Cell Mol Life Sci"},{"key":"3511_CR28","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1532\/IJH97.06140","volume":"84","author":"T Joshi","year":"2006","unstructured":"Joshi T, Butchar JP, Tridandapani S (2006) Fcgamma receptor signaling in phagocytes. Int J Hematol 84:210\u2013216. doi: 10.1532\/IJH97.06140","journal-title":"Int J Hematol"},{"key":"3511_CR29","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40560-014-0066-z","volume":"3","author":"S Nomura","year":"2015","unstructured":"Nomura S, Shimizu M (2015) Clinical significance of procoagulant microparticles. J Intensive Care 3:2. doi: 10.1186\/s40560-014-0066-z","journal-title":"J Intensive Care"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-016-3511-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00417-016-3511-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-016-3511-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T21:22:35Z","timestamp":1498339355000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00417-016-3511-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,17]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["3511"],"URL":"https:\/\/doi.org\/10.1007\/s00417-016-3511-y","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"type":"print","value":"0721-832X"},{"type":"electronic","value":"1435-702X"}],"subject":[],"published":{"date-parts":[[2016,10,17]]}}}